Laura Dichtel MD
Diabetes, Lipid Metabolism, Pituitary Disorders & Neuroendocrinology
Instructor In Medicine, Harvard Medical School and Assistant in Medicine, Massachusetts General Hospital
Join to View Full Profile
55 Fruit St# BUL457Boston, MA 02114
Phone+1 617-724-3614
Fax+1 617-726-5072
Dr. Dichtel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Massachusetts General HospitalFellowship, Endocrinology, Diabetes, and Metabolism, 2012 - 2015
Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2009 - 2012
Yale School of MedicineClass of 2009
Certifications & Licensure
MA State Medical License 2012 - 2027
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Clinical Trials
- The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease Start of enrollment: 2022 Aug 10
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- Adult Growth Hormone Deficiency (AGHD) and Outcomes (NordiNet and ANSWER).John D Carmichael, Atil Y Kargi, Laura Dichtel, Nicky Kelepouris, Navid Nedjatian
Journal of the Endocrine Society. 2025-03-03 - Neuroactive steroid levels are elevated in the follicular phase and predict premenstrual depression and anxiety symptom severity in women with menstrually related mood...Allison Kimball, Jenna Bourassa, Mark L Chicote, Anu V Gerweck, Laura E Dichtel
Archives of Women's Mental Health. 2024-11-27 - 1 citationsHigher serum myostatin levels are associated with lower insulin sensitivity in adults with overweight/obesity.Laura E Dichtel, Allison Kimball, Bryan Bollinger, Geetanjali Scarff, Anu V Gerweck
Physiological Reports. 2024-09-01
Press Mentions
Top in Endocrinology: Nonalcoholic Fatty Liver Disease in Patients with Obesity, DiabetesJune 29th, 2022- Lumos Pharma, Inc. (LUMO) CEO Richard Hawkins on Q1 2022 Results - Earnings Call TranscriptMay 11th, 2022
- Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated TrialMay 5th, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
